Research Institute of Molecular Pathology (IMP)
Harald Isemann was named Administrative Director of the privately-funded Institute of Molecular Pathology (IMP) in Vienna in February 2004. IMP is a subsidiary of Boehringer Ingelheim, one of the world's leading pharmaceutical companies. Headed by Prof. Kim Nasmyth, the Institute is a basic biomedical research center and is located within the Campus Vienna BioCenter, a center for molecular biology and genetic research. "My experience working with Technologie Impulse Ltd. (TIG), enabled me to acquire the necessary expertise for my current position at IMP," Mr. Isemann said, adding, "IMP's reputation as one of Europe's leading research institutions made the job offer particularly attractive for me."
Access to the full article is free, but requires you to register. Registration is simple and quick - all we need is your name and a valid e-mail address. We appreciate your interest in bridges.